Results of a multidisciplinary strategy to improve the management of cardiovascular risk factors after liver transplantation.
Journal
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
15
02
2022
received:
10
01
2022
accepted:
18
02
2022
pubmed:
1
3
2022
medline:
19
7
2022
entrez:
28
2
2022
Statut:
ppublish
Résumé
Although liver transplantation (LT) recipients are at high cardiovascular risk (CVR), the management of CVR factors (CVRF) after LT is far from optimal and needs to be improved. For this reason, we developed a multidisciplinary protocol to standardize the identification, risk stratification, management, and targets of therapy of CVRF during the first post-LT year. The grade of identification and control of CVRF 12 months after LT in the postintervention cohort (LT January 2018-January 2020, n = 150) were compared with a control cohort who underwent LT between July 2015 and December 2016 (n = 100). Before LT, the prevalence of metabolic-associated fatty liver disease as the indication of LT and the presence of obesity were significantly higher in the postintervention cohort, whereas the prevalence of other CVRF and renal dysfunction tended to be higher. Cyclosporine A was used less frequently in the postintervention cohort, whereas everolimus tended to increase. At 12 months after LT, the proportion of patients with measured blood pressure (88% vs. 56%), glycosilated hemoglobin (HbA1c; 96% vs. 72%), and high-density lipoprotein/low-density lipoprotein cholesterol (67% vs. 33%) was higher in the postintervention than in the control cohort (all p < 0.001). Blood pressure (64% vs. 36%, p = 0.02) and HbA1c (85% vs. 70%, p = 0.1) were within target in more individuals with hypertension and diabetes mellitus, respectively, in the postintervention cohort. Median total cholesterol levels were lower in the postintervention (184 mg/dl; interquartile range [IQR], 160-210 mg/dl) than in the control cohort (212 mg/dl; IQR, 186-240 mg/dl; p = 0.02). At 2 years after LT, the incidence of cardiovascular events was 14% in the control cohort and 6% in the postintervention cohort (p = 0.063). In conclusion, a multidisciplinary, multiprofessional strategy can achieve a higher grade of assessment and management of post-LT CVR despite a worsening metabolic profile of LT recipients.
Identifiants
pubmed: 35224857
doi: 10.1002/lt.26443
pii: 01445473-202208000-00011
doi:
Substances chimiques
Cholesterol, LDL
0
Glycated Hemoglobin A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1332-1344Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 American Association for the Study of Liver Diseases.
Références
Durand F, Levitsky J, Cauchy F, Gilgenkrantz H, Soubrane O, Francoz C. Age and liver transplantation. J Hepatol. 2019;70:745–58.
Crespo G, Trota N, Londoño M‐C, Mauro E, Baliellas C, Castells L, et al. The efficacy of direct anti‐HCV drugs improves early post‐liver transplant survival and induces significant changes in waiting list composition. J Hepatol. 2018;69:11–7.
Younossi ZM, Stepanova M, Ong J, Trimble G, AlQahtani S, Younossi I, et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clin Gastroenterol Hepatol. 2021;19:580–9.e5.
Stepanova M, Wai H, Saab S, Mishra A, Venkatesan C, Younossi ZM. The portrait of an adult liver transplant recipient in the United States from 1987 to 2013. JAMA Intern Med. 2014;174:1407–9.
VanWagner LB, Lapin B, Levitsky J, Wilkins JT, Abecassis MM, Skaro AI, et al. High early cardiovascular mortality after liver transplantation. Liver Transpl. 2014;20:1306–16.
Sastre L, García R, Gándara J‐G, Ruiz P, Lombardo J, Colmenero J, et al. Incidence, predictors, and impact on survival of long‐term cardiovascular events after liver transplantation. Transplantation. 2020;104:317–25.
Roccaro GA, Goldberg DS, Hwang W‐T, Judy R, Thomasson A, Kimmel SE, et al. Sustained posttransplantation diabetes is associated with long‐term major cardiovascular events following liver transplantation. Am J Transplant. 2018;18:207–15.
Martínez‐Saldivar B, Prieto J, Berenguer M, de la Mata M, Pons J‐A, Serrano T, et al. Control of blood pressure in liver transplant recipients. Transplantation. 2012;93:1031–7.
Alvarez‐Sotomayor D, Satorres C, Rodríguez‐Medina B, Herrero I, de la Mata M, Serrano T, et al. Controlling diabetes after liver transplantation: room for improvement. Transplantation. 2016;100:e66–73.
Patel SS, Rodriguez VA, Siddiqui MB, Faridnia M, Lin FP, Chandrakumaran A, et al. The impact of coronary artery disease and statins on survival after liver transplantation. Liver Transpl. 2019;25:1514–23.
Campbell PT, VanWagner LB. Mind the gap: statin underutilization and impact on mortality in liver transplant recipients. Liver Transpl. 2019;25:1477–9.
Harrington C, Kosirog M, Campbell P, Gregory D, Daud A, Levitsky J, et al. Poor practitioner adherence to clinical tobacco use guidelines in liver transplant recipients. Transplantation Direct. 2022;8:e1288.
VanWagner LB, Holl JL, Montag S, Gregory D, Connolly S, Kosirog M, et al. Blood pressure control according to clinical practice guidelines is associated with decreased mortality and cardiovascular events among liver transplant recipients. Am J Transplant. 2020;20:797–807.
VanWagner LB, Gordon E, Adamski L, Kosirog M, Daud A, Finn DJ, et al. Liver transplant recipient, caregiver, and provider perceptions of cardiovascular disease and related risk factors after transplant. Liver Transpl. 2021;27:668–83.
Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058.
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–81.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient‐centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9.
Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.
Goff DC Jr., Lloyd‐Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–73.
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero‐Gomez M, et al. A new definition for metabolic dysfunction‐associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–9.
VanWagner LB, Aghaulor B, Hussain T, Kosirog M, Campbell P, Pine S, et al. When evidence is lacking: a mixed‐methods approach for the development of practice guidance in liver transplantation. Gastroenterol Rep (Oxf). 2021;9:22–30.
[cited 2022 Apr 12]. Available from: https://www.aenor.com/certificacion/sanidad‐y‐servicios‐sociales/unidad‐trasplante‐hepatico .
Chaney AJ, Yataco ML. The emerging role of nurse practitioners and physician assistants in liver transplantation. Liver Transpl. 2019;25:1105–9.
Patel SS, Siddiqui MB, Chadrakumaran A, Faridnia M, Lin F‐P, Hernandez Roman J, et al. Office‐based weight loss counseling is ineffective in liver transplant recipients. Dig Dis Sci. 2020;65:639–46.
Charlton M, Rinella M, Patel D, McCague K, Heimbach J, Watt K. Everolimus is associated with less weight gain than tacrolimus 2 years after liver transplantation: results of a randomized multicenter study. Transplantation. 2017;101:2873–82.
Azhie A, Sheth P, Hammad A, Woo M, Bhat M. Metabolic complications in liver transplantation recipients: how we can optimize long‐term survival. Liver Transpl. 2021;27:1468–78.
Fatourou EM, Tsochatzis EA. Management of metabolic syndrome and cardiovascular risk after liver transplantation. Lancet Gastroenterol Hepatol. 2019;4:731–41.
Kotha S, Lawendy B, Asim S, Gomes C, Yu J, Orchanian‐Cheff A, et al. Impact of immunosuppression on incidence of post‐transplant diabetes mellitus in solid organ transplant recipients: systematic review and meta‐analysis. World J Transplant. 2021;11:432–42.
Syed T, Siddiqui MS. Atherogenic dyslipidemia after liver transplantation: mechanisms and clinical implications. Liver Transpl. 2021;27:1326–33.
Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: disease burden, current management and future challenges. JHEP Rep. 2020;2:100192.
Castells L, Baliellas C, Bilbao I, Cantarell C, Cruzado JM, Esforzado N, et al. Early detection, prevention and management of renal failure in liver transplantation. Gastroenterol Hepatol. 2014;37:480–91.
Nevens F, Pirenne J. Renal disease in the allograft recipient. Best Pract Res Clin Gastroenterol. 2020;46–47:101690.
Locke JE, Shelton B, Orandi B, Olthoff K, Pomfret E, Forde KA, et al. Obesity is a risk factor for progression to kidney transplant waitlisting after liver transplantation. Clin Transplant. 2021;35:e14317.
Winiarska A, Knysak M, Nabrdalik K, Gumprecht J, Stompór T. Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 inhibitors and GLP‐1 receptor agonists. Int J Mol Sci. 2021;22:10822.
Richardson B, Khan MQ, Brown SA, Watt KD, Izzy M. Personalizing diabetes management in liver transplant recipients: the new era for optimizing risk management. Hepatol Commun. 2022;6:1250–61.
Campbell PT, Kosirog M, Aghaulor B, Gregory D, Pine S, Daud A, et al. Comanagement with nephrologist care is associated with fewer cardiovascular events among liver transplant recipients with chronic kidney disease. Transplant Direct. 2021;7:e766.
Siddiqui MB, Arshad T, Patel S, Lee E, Albhaisi S, Sanyal AJ, et al. Small dense low‐density lipoprotein cholesterol predicts cardiovascular events in liver transplant recipients. Hepatology. 2019;70:98–107.
Sastre L, García R, Gándara J‐G, Fernández‐Llama P, Amor AJ, Sierra C, et al. The role of arterial stiffness in the estimation of cardiovascular risk in liver transplant recipients. Transplant Direct. 2022;8:e1272.
Lindbohm JV, Sipilä PN, Mars N, Knüppel A, Pentti J, Nyberg ST, et al. Association between change in cardiovascular risk scores and future cardiovascular disease: analyses of data from the Whitehall II longitudinal, prospective cohort study. Lancet Digit Health. 2021;3:e434–44.